New York State Teachers Retirement System Has $13.90 Million Stock Holdings in Biogen Inc. $BIIB
New York State Teachers Retirement System increased its stake in Biogen Inc. (NASDAQ:BIIB) by 2.8% in Q2, owning 110,649 shares valued at $13.90 million. Other institutional investors also adjusted their holdings. Insider Priya Singhal sold 517 shares, reducing ownership by 8.22%. Analysts have mixed ratings on Biogen, with a consensus rating of "Hold" and an average target price of $180.69. Biogen's stock opened at $143.00, with a market cap of $20.97 billion and a P/E ratio of 13.67.
New York State Teachers Retirement System raised its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 2.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 110,649 shares of the biotechnology company's stock after buying an additional 2,973 shares during the quarter. New York State Teachers Retirement System owned 0.08% of Biogen worth $13,896,000 at the end of the most recent reporting period.
- Biogen Stock Is Mutating Into a Value Play
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wedmont Private Capital grew its holdings in Biogen by 3.8% in the 2nd quarter. Wedmont Private Capital now owns 2,190 shares of the biotechnology company's stock valued at $291,000 after buying an additional 81 shares in the last quarter. Private Trust Co. NA raised its stake in Biogen by 74.8% in the first quarter. Private Trust Co. NA now owns 229 shares of the biotechnology company's stock valued at $31,000 after purchasing an additional 98 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in Biogen by 21.0% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 617 shares of the biotechnology company's stock valued at $77,000 after purchasing an additional 107 shares in the last quarter. Oregon Public Employees Retirement Fund raised its stake in Biogen by 0.9% in the first quarter. Oregon Public Employees Retirement Fund now owns 12,598 shares of the biotechnology company's stock valued at $1,724,000 after purchasing an additional 110 shares in the last quarter. Finally, Capital Investment Advisors LLC raised its stake in Biogen by 5.4% in the second quarter. Capital Investment Advisors LLC now owns 2,164 shares of the biotechnology company's stock valued at $272,000 after purchasing an additional 111 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, insider Priya Singhal sold 517 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $133.55, for a total transaction of $69,045.35. Following the completion of the sale, the insider owned 5,772 shares of the company's stock, valued at $770,850.60. This trade represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.18% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
- These 3 Stocks Are Screaming Oversold: Seize the Opportunity
A number of research analysts recently commented on BIIB shares. William Blair reaffirmed an "outperform" rating on shares of Biogen in a research note on Wednesday, September 24th. Royal Bank Of Canada dropped their price objective on Biogen from $219.00 to $217.00 and set an "outperform" rating for the company in a research report on Wednesday, October 8th. Morgan Stanley upped their price objective on Biogen from $144.00 to $149.00 and gave the stock an "equal weight" rating in a research report on Friday, October 10th. Wall Street Zen upgraded Biogen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 28th. Finally, Piper Sandler upped their price objective on Biogen from $115.00 to $118.00 and gave the stock a "neutral" rating in a research report on Friday, September 12th. Eleven investment analysts have rated the stock with a Buy rating, nineteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $180.69.
View Our Latest Report on BIIB
Biogen Trading Up 0.5%
- Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche
Shares of BIIB stock opened at $143.00 on Friday. The stock has a market cap of $20.97 billion, a price-to-earnings ratio of 13.67, a PEG ratio of 1.13 and a beta of 0.13. The stock has a 50-day moving average of $141.53 and a 200-day moving average of $131.43. The company has a current ratio of 2.50, a quick ratio of 1.79 and a debt-to-equity ratio of 0.36. Biogen Inc. has a 1-year low of $110.04 and a 1-year high of $191.19.
Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share for the quarter, beating the consensus estimate of $3.93 by $1.54. Biogen had a return on equity of 13.85% and a net margin of 15.31%.The company had revenue of $2.65 billion during the quarter, compared to analysts' expectations of $2.32 billion. During the same quarter in the prior year, the firm posted $5.28 earnings per share. The business's quarterly revenue was up 7.3% on a year-over-year basis. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS. On average, equities research analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current year.
Biogen Profile
(Free Report)Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.
Read More
- Five stocks we like better than Biogen
- How to Profit From Value Investing
- Johnson & Johnson's M&A Strategy Is the Real Story for Investors
- Investing in Commodities: What Are They? How to Invest in Them
- Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?
- How to Invest in Biotech Stocks
- Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Biogen Right Now?
Before you consider Biogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.
While Biogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
